SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
  • 2
    Dobruch J, Herr H. Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection? BJU Int. 2009; 104: 170-174.
  • 3
    Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003; 21: 1315-1330.
  • 4
    Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst. 2003; 95: 588-597.
  • 5
    Madeb R, Golijanin D, Noyes K, et al. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer. 2009; 115: 2660-2670.
  • 6
    Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996; 155: 1233-1238.
  • 7
    Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991; 325: 1205-1209.
  • 8
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40( 8 suppl): IV-3-IV-18.
  • 9
    Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002; 40( 8 suppl): IV-19-IV-25.
  • 10
    Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
  • 11
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
  • 12
    Gore JL, Litwin MS, Lai J, et al. Use of radical cystectomy for patients with invasive bladder cancer. J Natl Cancer Inst. 2010; 102: 802-811.
  • 13
    Miller DC, Saigal CS, Banerjee M, Hanley J, Litwin MS. Diffusion of surgical innovation among patients with kidney cancer. Cancer. 2008; 112: 1708-1717.
  • 14
    Hollingsworth JM, Zhang Y, Krein SL, Ye Z, Hollenbeck BK. Understanding the variation in treatment intensity among patients with early stage bladder cancer. Cancer. 2010; 116: 3587-3594.
  • 15
    Olsen LH, Genster HG. Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. Scand J Urol Nephrol Suppl. 1995; 172: 33-36.
  • 16
    Lamm DL. BCG immunotherapy in bladder cancer. In: Rouse SN, ed. Urology Annual. Los Angeles: Appleton and Lange; 1987: 67.
  • 17
    Pinsky CM, Camacho FJ, Kerr D et al. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat Rep. 1985; 69: 47-53.
  • 18
    Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002; 168: 1964-1970.
  • 19
    Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol. 1999; 161: 1120-1123.
  • 20
    Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004; 171( 6 pt 1): 2186-2190.
  • 21
    Ali-el-Dein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol. 1997; 79: 731-735.
  • 22
    Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmang S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol. 2008; 179: 101-105; discussion 105-106.
  • 23
    Gudjonsson S, Adell L, Merdasa F, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol. 2009; 55: 773-780.
  • 24
    Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993; 149: 749-752.
  • 25
    Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study–FinnBladder III long-term results. J Urol. 2002; 168: 981-985.
  • 26
    Rajala P, Liukkonen T, Raitanen M, et al. Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study–Finnbladder III. J Urol. 1999; 161: 1133-1135; discussion 1135-1136.
  • 27
    Cropper CM. The robot is in— and ready to operate. Business Week: March 14, 2005: 110-112.
  • 28
    Bowa K, Wood C, Chao A, Chintu C, Mudenda V, Chikwenya M. A review of the epidemiology of cancers at the University Teaching Hospital, Lusaka, Zambia. Trop Doct. 2009; 39: 5-7.
  • 29
    Schrag D, Mitra N, Xu F, et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology. 2005; 65: 1118-1125.
  • 30
    Strope SA, Ye Z, Hollingsworth JM, Hollenbeck BK. Patterns of care for early stage bladder cancer. Cancer. 2010; 116: 2604-2611.
  • 31
    van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003; 44: 429-434.
  • 32
    Surveillance, Epidemiology and End Results (SEER) Program. http://www.seer.cancer.gov. Accessed October 2010.
  • 33
    Federal Interagency Forum on Aging-Related Statistics. Older Americans Update 2006: Key Indicators of Well-Being. Washington, DC: US Government Printing Office; 2006.
  • 34
    Rosenthal MB, Landon BE, Normand SL, Frank RG, Epstein AM. Pay for performance in commercial HMOs. N Engl J Med. 2006; 355: 1895-1902.